I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| CD8-positive, alpha-beta T cell | 8 studies | 27% ± 10% | |
| CD4-positive, alpha-beta T cell | 6 studies | 30% ± 11% | |
| natural killer cell | 6 studies | 29% ± 10% | |
| B cell | 5 studies | 25% ± 3% | |
| pro-B cell | 5 studies | 30% ± 4% | |
| T cell | 5 studies | 28% ± 9% | |
| plasmablast | 4 studies | 39% ± 18% | |
| hematopoietic precursor cell | 4 studies | 29% ± 8% | |
| GABAergic neuron | 4 studies | 20% ± 1% | |
| glutamatergic neuron | 4 studies | 21% ± 2% | |
| effector CD8-positive, alpha-beta T cell | 4 studies | 23% ± 3% | |
| mast cell | 3 studies | 21% ± 4% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 21% ± 1% | |
| classical monocyte | 3 studies | 25% ± 8% | |
| conventional dendritic cell | 3 studies | 38% ± 6% | |
| epithelial cell | 3 studies | 33% ± 4% | |
| dendritic cell | 3 studies | 37% ± 3% | |
| transit amplifying cell | 3 studies | 38% ± 3% | |
| regulatory T cell | 3 studies | 23% ± 8% |
